Related Experiment Video

Updated: May 13, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549

Zhi-Yin Ke1, Tian Fu2, Xue-Chun Wang1

  • 1Department of Biochemistry and Molecular Biology & Department of Clinical Biochemistry, Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnosis, Guangdong Medical University, Dongguan, China.

Molecular & Cellular Oncology
|April 14, 2025
PubMed

Insights

Inhibiting CHK1 kinase combined with gemcitabine effectively reduces non-small cell lung cancer cell proliferation. This combination induces DNA damage and overcomes gemcitabine resistance, offering a potential new NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
  • Gemcitabine is a standard chemotherapy, but acquired resistance limits its efficacy.
  • Targeting cell cycle regulation and DNA repair pathways offers therapeutic opportunities.

Purpose of the Study:

  • To investigate the anti-proliferative effects of inhibiting CHK1 expression combined with gemcitabine in NSCLC cells.
  • To elucidate the underlying molecular mechanisms of this combination therapy.
  • To assess the potential of CHK1 inhibition to overcome gemcitabine resistance.

Main Methods:

  • Quantitative reverse transcription PCR (RT-qPCR) and Western blotting for gene and protein analysis.
  • Cell Counting Kit-8 (CCK-8) and colony formation assays for cell viability.
  • Annexin V/7-amino-actinomycin D staining for cell cycle analysis.
  • Immunofluorescence and alkaline comet assays for DNA damage assessment.

Main Results:

  • Combination therapy significantly inhibited NSCLC cell proliferation and induced apoptosis.
  • CHK1 inhibition led to DNA damage, γ-H2AX phosphorylation, and impaired homologous recombination repair.
  • Gemcitabine activated the ATR-CHK1-CDC25A pathway; CHK1 inhibition caused S phase arrest and mitotic catastrophe.

Conclusions:

  • Inhibition of CHK1 combined with gemcitabine demonstrates significant anti-proliferative activity in NSCLC.
  • This combination induces DNA damage and apoptosis, offering a novel therapeutic strategy.
  • Targeting CHK1 is a promising approach to overcome acquired gemcitabine resistance in NSCLC.
Keywords:
A549 cellsCHK1Non-small cell lung cancerdrug resistancegemcitabine

More Related Videos

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment09:56

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment

Published on: April 30, 2019

9.1K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K